SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
A study presented at Kidney Week 2026 indicates that SGLT2 inhibitors provide significant cardiovascular and kidney benefits to frail older adults with type 2 diabetes. Despite these findings, the medication remains underutilized in high-risk patient populations.
Why it matters
This research challenges clinical hesitation regarding prescribing advanced diabetes medications to frail patients, potentially improving long-term health outcomes for an aging demographic.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with lower risks of kidney and cardiovascular (CV) events in older adults with type 2 diabetes (T2D), including those who are frail, according to a real-world analysis from South Korea that will be presented at the American Society of Nephrology’s Kidney Week 2026 in Denver, Colorado. A second nationwide cohort study in the same poster session found that more than half of patients with T2D and albuminuria received neither an SGLT2 inhibitor nor a glucagon-like peptide-1 receptor agonist (GLP-1 RA). The largest gaps were among women, older adults, and patients with advanced chronic kidney disease (CKD).1,2
Frailty Did Not Erase the Benefit
Headlinne story · 3 newsrooms
New Studies Show Kidney Drugs Benefit Very Old Patients
What every outlet reported, where they differ, and how each framed it →
Also covering this story
2 other newsrooms covered this event. We read each version separately.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in